Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.
“The United States is an important market for us. The announcement of patent approval for inhaled drugs is extremely gratifying and important, as it strengthens our conditions to develop new unique and patent-protected pharmaceutical products for inhalation”, says Torbjörn W. Larsson, CEO of Emplicure.
The patent, U.S. Patent No. 11,202,871 will be valid into 2037. The information about the preliminary approval was published August 19, 2021.